Development of molecular assays based on epigenetic biomarkers which allow early and reliable cancer diagnostics – this is the intention of oncgnostics!
Our products should allow an early detection of diseases to substantially inprove therapy success. Notice: if detected early, almost all cancer cases are curable.
If you would like us to keep you informed about news related to our company, please sign in for our quarterly newsletter.
oncgnostics GmbH Susann Nuernberger / EUROIMMUN Medizinische Labordiagnostika AG
https://www.oncgnostics.com/wp-content/uploads/2021/03/210315_Vertrag_Euroimmun_Website.jpg
321
845
TowerPR
https://www.oncgnostics.com/wp-content/uploads/2015/03/oncgnostics-logo1-300x138.png
TowerPR2021-03-25 09:44:542021-03-25 09:44:54International sales partnership with EUROIMMUN for Distribution of GynTect
https://www.oncgnostics.com/wp-content/uploads/2021/03/1506_Blogbeitrag_PCR.jpg
321
845
TowerPR
https://www.oncgnostics.com/wp-content/uploads/2015/03/oncgnostics-logo1-300x138.png
TowerPR2021-03-24 16:11:232021-03-24 16:11:23PCR: Certainty in the shortest possible time
Eberhard Schorr / oncgnostics GmbH
https://www.oncgnostics.com/wp-content/uploads/2021/02/190329_1878HiRes_845px.jpg
321
845
TowerPR
https://www.oncgnostics.com/wp-content/uploads/2015/03/oncgnostics-logo1-300x138.png
TowerPR2021-02-18 05:00:252021-03-25 10:42:24Looking back on a successful year of researchOur fist product, GynTect®, enables reliable and fast diagnosis of cervical cancer and pre-cancerous stages.
Video in German.
